Medisafe, a personalised mobile health platform for medication management with over four million patient and caregiver users globally, yesterday announced a collaboration with Boehringer Ingelheim Pharmaceuticals Inc, a global, research-driven pharmaceutical company.
The collaboration is aimed at delivering an innovative new section within Medisafe's medication management platform for patients.
The company will provide access within the overall Medisafe app to a section with educational materials specific to Boehringer Ingelheim's Pradaxa, including health literacy videos, relevant health tips and a Pradaxa Savings Card, to certain individuals who are taking Pradaxa.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients